Citations to this article
Abstract
Acquired resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) limits their therapeutic benefits in patients with high-grade serous ovarian cancer (HGSC). Identifying therapeutic vulnerabilities that function across distinct forms of acquired PARPi resistance is an urgent need. In BRCA2-deficient PARPi-naive cells, targeting RAD52 can be synthetic lethal with a PARPi, making RAD52 an attractive therapeutic target. However, this approach has not been tested in HGSC models of acquired PARPi resistance. Here, we assessed the effects of RAD52 loss in 2 distinct Brca2-deficient mouse models of HGSC with acquired PARPi resistance. RAD52 loss suppressed homologous recombination and single-strand annealing DNA repair activity in both models. Genetic depletion and pharmacologic inhibition of RAD52 restored PARPi sensitivity both in vitro and in vivo. Furthermore, RAD52 expression was elevated in a newly derived human model of BRCA2-deficient HGSC with acquired PARPi resistance. In this cell line, RAD52 inhibition synergized with a PARPi. Finally, elevated RAD52 expression was associated with poor survival in patients with HGSC. Collectively, these findings establish RAD52 as a clinically relevant therapeutic vulnerability in multiple models of HGSC with acquired PARPi resistance.
Authors
Yukihide Ota, Maia L. Elizagaray, Vijayalaxmi Gupta, Bisiayo E. Fashemi, Moreniola Akande, Preedia Babu, Prasanth Kumar Thuthika, Elena Lomonosova, Joshua Brill, Lulu Sun, Brooke Sanders, Lindsay M. Kuroki, Carolyn K. McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David G. Mutch, Matthew A. Powell, Krzysztof Hyrc, Priyanka Verma, John Krais, Benjamin G. Bitler, Mary M. Mullen, Dineo Khabele
Loading citation information...
